title: Telomerase activity in central nervous system malignant lymphoma.
abstract: BACKGROUND
  Primary central nervous system malignant lymphoma (PCNSL) has been regarded as a rare neoplasm. Recently, however, its incidence has been rapidly increasing. Despite active clinical trials, its clinical and biologic features remain unknown and there has been no effective treatment or prognostic factor. The current study attempted to elucidate telomerase activity and expression of the telomere-related RNA of PCNSL as novel prognostic factors.
  
  
  METHODS
  The subjects were 12 patients with histologically diagnosed PCNSL. All patients were treated with chemoradiotherapy consisting of whole-brain radiation, vincristine, etoposide, and prednisolone. Telomerase activity in the resected tumor was analyzed both qualitatively and quantitatively using the TRAP (telomeric amplification assay protocol)/TRAP-HPA (hybridization protection assay) method. The expression of telomere-related RNA (hTERT, hTERC, and TEP1) was analyzed by reverse transcriptase-polymerase chain reaction.
  
  
  RESULTS
  Telomerase activity was detected in 10 of 12 patients with PCNSL, with an average activity of 148.9 relative light units. The average telomere length was 5.55 kb. The expression of hTERT correlated with telomerase activity, and there was a statistically significant correlation between telomerase activity and both the duration of survival and the interval to tumor progression.
  
  
  CONCLUSIONS
  Telomerase activity and the expression of hTERT may be novel prognostic factors in patients with PCNSL.
authors.affiliation: Department of Neurosurgery, School of Medicine, Hiroshima University, Hiroshima, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Harada
authors.forename: K
authors.initials: K
authors.lastname: Kurisu
authors.forename: K
authors.initials: K
authors.lastname: Arita
authors.forename: T
authors.initials: T
authors.lastname: Sadatomo
authors.forename: H
authors.initials: H
authors.lastname: Tahara
authors.forename: E
authors.initials: E
authors.lastname: Tahara
authors.forename: T
authors.initials: T
authors.lastname: Ide
authors.forename: T
authors.initials: T
authors.lastname: Uozumi
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000532:radiotherapy; D020134:Catalytic Domain; D003131:Combined Modality Therapy; D004268:DNA-Binding Proteins; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000201:enzymology* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D012313:RNA; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016019:Survival Analysis; D019098:Telomerase / Q000032:analysis / Q000378:metabolism*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D004268:DNA-Binding Proteins; C422952:telomerase RNA; D014750:Vincristine; D012313:RNA; D005047:Etoposide; D011239:Prednisolone; D019098:Telomerase